Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026)

Mangoceuticals' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$3.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 27.98% year-over-year to -$3.7 million; the TTM figure through Mar 2026 stood at -$20.1 million (down 70.73% YoY), while the FY2025 annual figure was -$21.8 million, down 129.47% from the prior year.
• Net Income towards Common Stockholders came in at -$3.7 million for Q1 2026 at Mangoceuticals, down from -$3.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.9 million in Q3 2025.
• A 4-year average of -$3.3 million and a median of -$2.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 245.02% in 2025 and increased 27.98% in 2026, its largest moves.
• Mangoceuticals' Net Income towards Common Stockholders stood at -$2.6 million in 2023, then gained by 24.13% to -$1.9 million in 2024, then sank by 57.24% to -$3.1 million in 2025, then retreated by 20.68% to -$3.7 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$3.7 million, -$3.1 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison